Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Chapter 1: Screening, diagnosis & staging of breast cancer and multidisciplinary team working

Multidisciplinary work

Breast Cancer-Essentials-Fig1.13

Figure 1.13: A multidisciplinary team meeting.
Credit: Dr Mazen Sudah, Department of Radiology, Kuopio University Hospital, Dr Katja Hukkinen, Department of Radiology, Helsinki University Hospital and Dr Päivi Heikkilä, Department of Pathology, Helsinki University Hospital.

All BC patients should have their case discussed at a multidisciplinary team meeting, pre- and post-surgery. Advanced BC should be discussed when a treatment decision is necessary. 

The team should include a breast surgeon, a medical oncologist, a radiation oncologist, a radiologist and a pathologist. In addition, nurses experienced in the care of patients with BC are essential team members. 

Plastic surgeons, nuclear medicine specialists, geneticists, physiotherapists and social workers may also contribute substantially to treatment planning.

Breast Cancer-Essentials-Fig1.14

Figure 1.14: Example of pathology report.
Abbreviations: DCIS, ductal carcinoma in situ.
Credit: Dr Mazen Sudah, Department of Radiology, Kuopio University Hospital, Dr Katja Hukkinen, Department of Radiology, Helsinki University Hospital and Dr Päivi Heikkilä, Department of Pathology, Helsinki University Hospital.

The pathology report should include the dimensions of the tumour(s) and the width of the surgical margins in millimetres. Cancer histological type and grade and presence of lymphovascular invasion are also reported. 

The number of examined regional LNs, LNs containing cancer, the size of the largest nodal metastatic deposit and any presence of cancer growth beyond the node capsule should be reported. 

At the minimum, tumour biological profiling includes testing for oestrogen receptor (ER), progesterone receptor (PgR), HER2 and Ki-67. Gene expression arrays and other genetic tests may assist in decision-making for adjuvant therapy.

Breast Cancer-Essentials-Fig1.15

Figure 1.15: Personalised sequence of treatments.
Credit: courtesy of M. Leidenius.

The sequence and timing of staging examinations, neoadjuvant and adjuvant systemic therapies, selection of the type of surgery, breast reconstruction and RT are optimised at the team meeting

The fluent flow and the exact documentation of information from all parties are essential for successful multidisciplinary teamwork.

Revision questions
  1. What are the goals of a multidisciplinary team meeting?
  2. Which healthcare professionals should be included in the core team?
  3. What information should be available in the pathology laboratory report?
Other staging examinations Breast cancer screening

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.